Literature DB >> 21683433

An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme.

Derek F Ceccarelli1, Xiaojing Tang, Benoit Pelletier, Stephen Orlicky, Weilin Xie, Veronique Plantevin, Dante Neculai, Yang-Chieh Chou, Abiodun Ogunjimi, Abdallah Al-Hakim, Xaralabos Varelas, Joanna Koszela, Gregory A Wasney, Masoud Vedadi, Sirano Dhe-Paganon, Sarah Cox, Shuichan Xu, Antonia Lopez-Girona, Frank Mercurio, Jeff Wrana, Daniel Durocher, Sylvain Meloche, David R Webb, Mike Tyers, Frank Sicheri.   

Abstract

In the ubiquitin-proteasome system (UPS), E2 enzymes mediate the conjugation of ubiquitin to substrates and thereby control protein stability and interactions. The E2 enzyme hCdc34 catalyzes the ubiquitination of hundreds of proteins in conjunction with the cullin-RING (CRL) superfamily of E3 enzymes. We identified a small molecule termed CC0651 that selectively inhibits hCdc34. Structure determination revealed that CC0651 inserts into a cryptic binding pocket on hCdc34 distant from the catalytic site, causing subtle but wholesale displacement of E2 secondary structural elements. CC0651 analogs inhibited proliferation of human cancer cell lines and caused accumulation of the SCF(Skp2) substrate p27(Kip1). CC0651 does not affect hCdc34 interactions with E1 or E3 enzymes or the formation of the ubiquitin thioester but instead interferes with the discharge of ubiquitin to acceptor lysine residues. E2 enzymes are thus susceptible to noncatalytic site inhibition and may represent a viable class of drug target in the UPS.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683433     DOI: 10.1016/j.cell.2011.05.039

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  101 in total

Review 1.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

2.  Insights into ubiquitin-conjugating enzyme/ co-activator interactions from the structure of the Pex4p:Pex22p complex.

Authors:  Chris Williams; Marlene van den Berg; Santosh Panjikar; Will A Stanley; Ben Distel; Matthias Wilmanns
Journal:  EMBO J       Date:  2011-11-15       Impact factor: 11.598

3.  Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites.

Authors:  Gregory R Bowman; Phillip L Geissler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

4.  Covalent Inhibition of Ubc13 Affects Ubiquitin Signaling and Reveals Active Site Elements Important for Targeting.

Authors:  Curtis D Hodge; Ross A Edwards; Craig J Markin; Darin McDonald; Mary Pulvino; Michael S Y Huen; Jiyong Zhao; Leo Spyracopoulos; Michael J Hendzel; J N Mark Glover
Journal:  ACS Chem Biol       Date:  2015-05-01       Impact factor: 5.100

5.  Molecular and structural insight into lysine selection on substrate and ubiquitin lysine 48 by the ubiquitin-conjugating enzyme Cdc34.

Authors:  Randy Suryadinata; Jessica K Holien; George Yang; Michael W Parker; Elena Papaleo; Boris Šarčević
Journal:  Cell Cycle       Date:  2013-05-08       Impact factor: 4.534

6.  In the family with ubiquitin.

Authors:  Gabriela Alexandru; Nonia Pariente; Dimitris Xirodimas
Journal:  EMBO Rep       Date:  2011-09-01       Impact factor: 8.807

7.  Discovery of multiple hidden allosteric sites by combining Markov state models and experiments.

Authors:  Gregory R Bowman; Eric R Bolin; Kathryn M Hart; Brendan C Maguire; Susan Marqusee
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

Review 8.  Protein-protein interaction modulators: advances, successes and remaining challenges.

Authors:  Lloyd Mabonga; Abidemi Paul Kappo
Journal:  Biophys Rev       Date:  2019-07-12

Review 9.  Structural and functional insights to ubiquitin-like protein conjugation.

Authors:  Frederick C Streich; Christopher D Lima
Journal:  Annu Rev Biophys       Date:  2014       Impact factor: 12.981

Review 10.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.